Delivery Order SPE2DB22D3301-SPE2DB25FX9AK

Award Date 1/27/25
Potential Completion Date 1/28/25
Potential Value $7.4K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $13,313.85 firm-fixed-price contract is for the supply of HAVRIX 1,440 UNIT/ML SYRINGEML, a vaccine product. The contract has an ultimate completion date of February 10, 2025. This appears to be a delivery order under a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop...
This is a delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,181.66, is for the supply of HAVRIX 720 unit/0.5 mL syringes. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that Amerisourcebergen holds with the DLA Troop Support Medical, which serves as a primary vehicle for providing a...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of HAVRIX 720 UNIT/0.5 ML SYRINGE 0.5ML, a vaccine product, with a ceiling value of $1,467.81 and a period of performance through January 22, 2024. This order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 between AmerisourceBergen and the DLA Troop...
This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,024.40, is for the delivery of HAVRIX 720 Unit/0.5 mL syringes, a vaccine product, to support medical requirements. The contract has a completion date of January 14, 2025 and is structured as a Firm Fixed Price Delivery Order. Amerisourcebergen holds a larger $999,999,999 Indefinite Delivery...
This is a delivery order issued by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor, for the supply of HAVRIX 720 unit/0.5 ML syringes. The contract is a firm fixed-price delivery order with a ceiling value of $1,175.94 and an ultimate completion date of August 30, 2024. This contract is not set aside for any specific business type. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $4,157.45, is for the supply of 4,567,461,416 units of the HAVRIX 720 vaccine syringe 0.5 mL. The award does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This is a $1,749.48 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of HAVRIX 720 UNIT/0.5 ML SYRINGE 0.5ML medical supplies, with a completion date of January 24, 2025. The contract is not designated as a set-aside. Amerisourcebergen Drug Corp holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp., a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 4,560,839 units of the HAVRIX 720 UNIT/0.5 ML SYRINGE 0.5ML vaccine, with a total ceiling value of $1,347.50. The contract has a firm fixed price pricing type and an ultimate completion date of May 8, 2023. This contract is not designated as a set-aside. AmerisourceBergen holds...
This federal contract award, valued at $1,833.70, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of HAVRIX 1,440 UNIT/ML SYRINGEML, a vaccine product, with a completion date of February 13, 2023. The contract is a firm fixed-price delivery order, and there is no set-aside designation indicated. AmerisourceBergen holds a significant Indefinite Delivery...
This is a $1,027.23 firm-fixed-price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The order is for HAVRIX 1,440 UNIT/ML syringes and has an ultimate completion date of April 17, 2023. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, which provides a comprehensive range of pharmaceutical...
  • SPE2DB22D3301
    Indefinite Delivery Contract
  • SPE2DB22D3301-SPE2DB25FX9AK
    Delivery Order

This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of HAVRIX 1,440 UNIT/ML SYRINGEML, a vaccine product. The contract has a firm fixed price of $7,391.70 and a completion date of January 28, 2025. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract award did not utilize any set-aside designations, indicating open competition.

Generated 4/28/25, 9:56 AM